Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers

智通财经07-20

Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Personalis 顶尖 MRD 技术与 Tempus 商业化能力、多模态数据与 AI 平台强化癌症全程监测能力、深化临床数据洞察、加速业务增长。交易将拓宽 Tempus 在癌症全诊疗周期的能力版图抢占高速增长、规模达200 亿美元的 MRD 肿瘤监测赛道。以下为公告原文：AI ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2652155242?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-20 20:39","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2652155242","market":"us","top_or_hot":-1,"title":"Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers","media":"智通财经","content":"<div>\n<p>Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Personalis 顶尖 MRD 技术与 Tempus 商业化能力、多模态数据与 AI 平台强化癌症全程监测能力、深化临床数据洞察、加速业务增长。交易将拓宽 Tempus 在癌症全诊疗周期的能力版图抢占高速增长、规模达200 亿美元的 MRD 肿瘤监测赛道。以下为公告原文：AI ...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-20 20:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Personalis 顶尖 MRD 技术与 Tempus 商业化能力、多模态数据与 AI 平台强化癌症全程监测能力、深化临床数据洞察、加速业务增长。交易将拓宽 Tempus 在癌症全诊疗周期的能力版图抢占高速增长、规模达200 亿美元的 MRD 肿瘤监测赛道。以下为公告原文：AI 精准...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2652155242","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652155242","pubTimestamp":1784551140,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Personalis 顶尖 MRD 技术与 Tempus 商业化能力、多模态数据与 AI","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PSNL":"Personalis","BK4613":"AI应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","TEMT":"2倍做多TEM ETF-Tradr","HEAL":"Global X HealthTech ETF","BK4121":"生命科学工具和服务","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4611":"AI医疗","ARKG":"ARK Genomic Revolution ETF","TEM":"Tempus AI"},"translate_title":"Tempus AI acquires Personalis to deeply integrate molecular residual lesions (MRD) into AI precision tumor treatment platform. This merger and acquisition combines Pers","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.98,"TEMT":0.6,"HEAL":0.6,"PSNL":1.96,"ARKG":0.6},"content_text":"Tempus AI收购Personalis将分子残留病灶（MRD）深度整合进AI 精准肿瘤治疗平台本次并购结合 Personalis 顶尖 MRD 技术与 Tempus 商业化能力、多模态数据与 AI 平台强化癌症全程监测能力、深化临床数据洞察、加速业务增长。交易将拓宽 Tempus 在癌症全诊疗周期的能力版图抢占高速增长、规模达200 亿美元的 MRD 肿瘤监测赛道。以下为公告原文：AI 精准医疗龙头 Tempus AI（NASDAQ: TEM）今日官宣已签署最终协议收购基因组精准肿瘤学企业 Personalis（NASDAQ: PSNL）。本次收购将大幅补强 Tempus 分子残留病灶（MRD） 核心能力覆盖癌症诊疗全流程：从早期诊断、用药方案选择到术后复发监测、长期随访。交易条款Personalis 每股收购对价 16.25 美元扣除 Tempus 原有持股后本次交易企业价值 15 亿美元。本次并购属于强强互补：双方自 2023 年 11 月建立战略合作Tempus 此前已投资 Personalis、并独家商业化其王牌产品 NeXT Personal® MRD 检测。并购后Tempus 的多模态医疗数据、AI 算法、肿瘤诊疗产品矩阵将与 Personalis 业内顶尖的肿瘤溯源 MRD 超高灵敏度测序技术深度融合实现癌症长期动态监测、生物标志物挖掘、个性化抗癌治疗全面升级。Tempus CEO Eric Lefkofsky：“MRD 是体量巨大、增速极快的赛道能够彻底改变癌症复发监测方式帮助医生更早、更精准判断复发风险。我们过去的合作已经证明：顶尖 MRD 技术 + Tempus 商业化与 AI 数据平台 = 极强临床价值。随着临床渗透率与医保报销持续落地我们将完整吃下这条 200 亿级赛道红利本次并购极具战略价值。”美国每年新增约 210 万癌症病例癌症患者生存期持续拉长术后长期复发监测需求爆发式增长。Personalis 的超高灵敏度 MRD 检测可捕捉极微量循环肿瘤 DNA（ctDNA）精准判断治疗效果、识别残留病灶、提前预警癌症复发。目前该技术已获得美国医保覆盖三大适应症更多报销落地在即商业化确定性极高。Personalis CEO Chris Hall：“本次并购是公司发展的关键里程碑。结合 Tempus 的规模、AI 平台、商业化渠道与资金资源我们可以加速技术迭代、大幅扩大患者触达。经过全面评估Tempus 是对股东价值最高、临床落地速度最快的最优合作方。”。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652155242","isCrawlerRequest":true}